Siegfried Holding - 股票

Siegfried Holding AAQS 2024

Siegfried Holding AAQS

7

股票代码

SFZN.SW

ISIN

CH0014284498

WKN

891169

Siegfried Holding当前的AAQS为7。

高AAQS可以被视为公司成功发展的积极迹象。

投资者可以预期该公司在带来盈利方面有很好的前景。

另一方面,将Siegfried Holding的股票AAQS与其他同行业公司及其获得的利润进行对比既重要。高AAQS并不是成功的绝对保证。只有这样,你才能得到公司绩效的全面图片。

为了更好地评估公司的发展,将AAQS与其他同行业公司进行对比是必要的。一般来说,投资者在决定投资时,应该结合其他众多指标,如利润、EBIT、现金流等来看待一个公司的AAQS。

Siegfried Holding Aktienanalyse

Siegfried Holding在做什么?

The Siegfried Holding AG is a Swiss pharmaceutical company based in Zofingen, which operates worldwide. The company's history dates back to 1873, when the pharmacist and chemist Franz von Siegfried founded the "First Aid Pharmacy". Over the years, the company has developed into an important producer of pharmaceutical ingredients. The business model of Siegfried Holding AG is based on the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. The products are used in various areas, such as veterinary medicine, human medicine, or the chemical industry. Siegfried operates various divisions that focus on different segments of the value chain. These divisions include production, contract development and manufacturing (CDMO), and commercial products. In the production division, the company produces pharmaceutical ingredients and intermediate products. The CDMO business offers custom development and manufacturing services for the pharmaceutical and biotech industry. In the commercial products division, finished products such as cough medicine, antidepressants, or blood pressure reducers are distributed. Among the products offered by Siegfried are the active ingredient carbamazepine, which is used as an anticonvulsant and for the treatment of bipolar disorder. Another active ingredient is acetaminophen, which is used as a painkiller and fever reducer. Siegfried also produces the active ingredient sotalol, which is used to treat heart rhythm disorders. In the context of the CDMO business, Siegfried also develops and produces custom products for the pharmaceutical and biotech industry. This includes the manufacturing of clinical trial preparations, the implementation of process developments, and scale-up productions of active ingredients and finished products. In recent years, Siegfried Holding AG has made several acquisitions to expand its business and strengthen its market presence. In 2016, the company acquired Bexbach-based Saltigo GmbH, a specialist in the production of customer-specific fine chemicals. Two years later, Siegfried acquired the active ingredient production business of Alcami, a US pharmaceutical company. In summary, it can be said that Siegfried Holding AG is an established Swiss pharmaceutical company specializing in the production and distribution of pharmaceutical ingredients, intermediate products, and finished products. In recent years, the company has made several acquisitions to expand its market presence and diversify its business. Siegfried Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

关于Siegfried Holding股票的常见问题

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Andere Kennzahlen von Siegfried Holding

我们对Siegfried Holding 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Siegfried Holding 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: